IFRX
HEALTHCAREInflaRx N.V.
$2.50+0.53 (+26.90%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving IFRX Today?
No stock-specific AI insight has been generated for IFRX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.71$2.94
$2.50
Fundamentals
Market Cap$181M
P/E Ratio—
EPS$-0.80
Dividend Yield—
Dividend / Share—
ROE-0.9%
Profit Margin—
Debt / Equity—
Trading
Volume18.3M
Avg Volume (10D)—
Shares Outstanding72.3M
IFRX News
20 articles- InflaRx Investor Update: Izicopan Set to Take Center Stage in AAV and Renal Disease PipelineMarketbeat·May 8, 2026
- InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary SharesYahoo Finance·May 8, 2026
- InflaRx N.V. (IFRX) Regains Compliance With NasdaqYahoo Finance·May 7, 2026
- InflaRx Announces Pricing of $150 Million Underwritten Offering of Ordinary SharesYahoo Finance·May 6, 2026
- InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal DiseasesYahoo Finance·May 6, 2026
- InflaRx Reports Favorable Reactive Metabolite Profile for Izicopan in Human Liver MicrosomesYahoo Finance·May 4, 2026
- InflaRx to Report First Quarter 2026 Results on May 7, 2026Yahoo Finance·May 1, 2026
- InflaRx Regains Compliance with Nasdaq Minimum Bid Price RequirementYahoo Finance·Apr 28, 2026
- April 2026 Penny Stocks To Watch For Potential GrowthYahoo Finance·Apr 16, 2026
- InflaRx Reports New Mechanistic Data for Izicopan Supporting its Potential as a Best-in-Class C5aR InhibitorYahoo Finance·Apr 9, 2026
- Revance CEO Nadeem Moiz on Expansion, Opportunities & CapitalizationYahoo Finance·Apr 7, 2026
- InflaRx Announces Participation in the Raymond James 2026 Biotech Innovation SymposiumYahoo Finance·Mar 31, 2026
- InflaRx Highlights Clinical Activity of Vilobelimab in Pyoderma Gangrenosum in Late-Breaker Oral Presentation at 2026 American Academy of Dermatology Annual MeetingYahoo Finance·Mar 30, 2026
- InflaRx N.V. (IFRX) Reports Q4 Loss, Lags Revenue EstimatesYahoo Finance·Mar 19, 2026
- InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected MilestonesYahoo Finance·Mar 19, 2026
- InflaRx Announces Late-Breaker Oral Presentation on Vilobelimab Phase 3 Results in Pyoderma Gangrenosum at 2026 American Academy of Dermatology Annual MeetingYahoo Finance·Mar 18, 2026
- InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price RequirementYahoo Finance·Mar 13, 2026
- InflaRx to Report Full Year 2025 Results on March 19, 2026Yahoo Finance·Mar 12, 2026
- InflaRx Announces Participation in the Leerink Partners Global Healthcare ConferenceYahoo Finance·Feb 26, 2026
- InflaRx Showcases Izicopan HS and CSU Data, Streamlines C5aR Strategy at Oppenheimer ConferenceMarketbeat·Feb 26, 2026
All 20 articles loaded
Price Data
Open$0.00
Previous Close$1.97
Day High$0.00
Day Low$0.00
52 Week High$2.94
52 Week Low$0.71
52-Week Range
$0.71$2.94
$2.50
Fundamentals
Market Cap$181M
P/E Ratio—
EPS$-0.80
Dividend Yield—
Dividend / Share—
ROE-0.9%
Profit Margin—
Debt / Equity—
Trading
Volume18.3M
Avg Volume (10D)—
Shares Outstanding72.3M
About InflaRx N.V.
InflaRx NV, a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company is headquartered in Jena, Germany.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—